Anixa Biosciences (ANIX) Cash from Operations (2010 - 2025)
Anixa Biosciences' (ANIX) quarterly Cash from Operations came in at 1255000.0 in Q4 2025, down 35.38% YoY from 1942212.02 in Q4 2024, and up 16.94% on a QoQ basis from 1511000.0 in Q3 2025.
Anixa Biosciences (ANIX) Cash from Operations (2010 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of Cash from Operations data on file, last reported at 1255000.0 in Q4 2025.
- Quarterly Cash from Operations fell 35.38% year-over-year to 1255000.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was 7173000.0 (up 2.21% YoY) and the FY2025 annual result came in at 7173000.0, up 2.21% from the prior year.
- Cash from Operations grew to 1255000.0 in Q4 2025, from 1511000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 807000.0 in Q2 2023 to a low of 2904000.0 in Q1 2025.
- A 5-year average of 1607350.0 and a median of 1468500.0 in 2021 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 85.67% — and 2023, when it jumped 65.0%.
- Tracing ANIX's Cash from Operations over 5 years: stood at 1045000.0 in 2021, then plunged by 52.44% to 1593000.0 in 2022, then retreated by 23.6% to 1969000.0 in 2023, then jumped by 52.92% to 927000.0 in 2024, then slumped by 35.38% to 1255000.0 in 2025.
- The last three Cash from Operations figures came in at 1255000.0 (Q4 2025), 1511000.0 (Q3 2025), and 1503000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Anixa Biosciences | 121.44 Mn | 121.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | -1.26 Mn |
| Oct 31, 2025 | -1.26 Mn |
| Jul 31, 2025 | -1.51 Mn |
| Jul 31, 2025 | -1.51 Mn |
| Apr 30, 2025 | -1.50 Mn |
| Apr 30, 2025 | -1.50 Mn |
| Jan 31, 2025 | -2.90 Mn |
| Jan 31, 2025 | -2.90 Mn |
| Oct 31, 2024 | -927,000.00 |
| Oct 31, 2024 | -927,000.00 |
| Jul 31, 2024 | -2.64 Mn |
| Jul 31, 2024 | -2.64 Mn |
| Apr 30, 2024 | -1.46 Mn |
| Apr 30, 2024 | -1.46 Mn |
| Jan 31, 2024 | -2.31 Mn |
| Jan 31, 2024 | -2.31 Mn |
| Oct 31, 2023 | -1.97 Mn |
| Oct 31, 2023 | -1.97 Mn |
| Jul 31, 2023 | -1.45 Mn |
| Jul 31, 2023 | -1.45 Mn |